



PRESS RELEASE

PsychoGenics and Sunovion Pharmaceuticals Inc. Expand Their Drug Discovery Partnership

TARRYTOWN, N.Y., June 17, 2013 – PsychoGenics Inc. and Sunovion Pharmaceuticals Inc. announced that they have expanded the scope of their CNS drug discovery partnership and extended the agreement for another two years.

The expanded agreement builds on the success of the partnership that has given rise to several CNS discovery programs. Sunovion and PsychoGenics will continue to advance existing discovery programs, as well as, screen new diverse compound libraries *in vivo* using PsychoGenics' proprietary SmartCube[®] system and broad preclinical capabilities, with the aim of identifying new therapies for CNS disorders.

“The phenotypic approach to drug discovery has historically yielded many of the most important CNS drugs”, said Tom Large, Senior Vice President of Discovery Research at Sunovion Pharmaceuticals Inc. “The PsychoGenics and Sunovion team has rapidly and efficiently utilized the rich behavioral data of SmartCube[®] to drive chemistry optimization efforts. This has yielded a drug-like molecule with novel pharmacology.”

“We are delighted to expand our shared-risk partnership with Sunovion which has already delivered a clinical candidate. We have enjoyed an excellent working relationship with the talented Sunovion discovery team and look forward to advancing existing discovery programs and pursuing new research programs together.” remarked Emer Leahy, Ph.D., PsychoGenics' President & Chief Executive Officer.

PsychoGenics' technologies, which include its SmartCube[®] system, combine broad *in vivo* behavioral expertise with developments in robotics, computer vision, and bioinformatics to phenotypically evaluate drug candidates for potential utility across the spectrum of CNS disease indications. Working in partnership with pharmaceutical and biotech companies, PsychoGenics has been instrumental in identifying therapeutic potential for discontinued compounds; as well as, early stage compounds with novel mechanisms of action.

About PsychoGenics

PsychoGenics is a leader in *in vivo* phenotypic drug discovery. The Company applies its proprietary technology platforms in partnership with pharmaceutical and biotechnology companies to discover the next generation of drugs for neuropsychiatric disorders. PsychoGenics' capabilities also include standard behavioral testing, electrophysiology, molecular biology, and state-of-the-art microdialysis. In addition, the company offers a variety of in-licensed transgenic mouse models that support research in areas such as Huntington's disease, autism spectrum disorders, psychosis/schizophrenia, Parkinson's disease, Spinal Muscular Atrophy, muscular dystrophy and other muscle disorders.

For more information contact:

Dr. Emer Leahy

President & CEO

Ph: (914) 406-8000

Email: info@psychogenics.com

www.psychogenics.com

